恒瑞医药：HRS-4357注射液、HRS-5041片获准开展临床试验

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-4357 injection and HRS-5041 tablets, indicating progress in its drug development pipeline for prostate cancer treatment [1] Group 1 - The company and its subsidiaries, Chengdu Shengdi Pharmaceutical Co., Ltd. and Tianjin Heng Rui Medicine Co., Ltd., will conduct clinical trials for HRS-4357 and HRS-5041 [1] - The clinical study will focus on the safety, tolerability, and preliminary efficacy of HRS-4357 in combination with HRS-5041 for treating PSMA-positive prostate cancer [1] - The trials are categorized as open-label, multi-center, and will be conducted in phases Ib/II [1]